OrbiMed
About OrbiMed
OrbiMed is a leading healthcare investment firm with over 25 years of global experience. The firm seeks to invest in world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, funding early-stage to multinational enterprises. With a team of more than 150 professionals and approximately $20 billion in assets under management, OrbiMed provides tailored financing and global resources to help build world-class healthcare companies worldwide.
Recent News
Terremoto Wins $108m in Series C to Drive Cancer and Rare Disease Programmes
Aspen Neuroscience Lands $115M Series C
Accro Bioscience Secures $50 Million Series C Led by OrbiMed to Advance Ulcerative Colitis Drug
Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics
Mendra Raises $82M in Series A Funding
Pulnovo Medical Raises $100 Million in Strategic Round Led by Medtronic
Syneron Raises $150m for Macrocyclics, and Other Financings
How to Invest in Healthcare's Powerful Growth
SpectronRx Raises $85 Million to Expand Isotope Production and Manufacturing Capacity
Amid Ownership Transition, Sirona’s Revenue Drops to Rs 77 Cr in FY25
Argenx Names New CEO; Van Hauwermeiren to Become Chair
Radiopharma Firm Secures $85M to Expand Domestic Production of Radioisotopes
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Terremoto Raises $108M to Pursue Development of Drugs Targeting AKT
Q32 Bio Raises $55M as Guardant, Soligenix, Novavax Lead Biotech Gains
Adcendo Raises $75M to Advance Cancer Drug Pipeline
BlossomHill Therapeutics Inks $84M Series B Extension
Sidewinder Targets Solid Tumors with Bispecific ADCs on Novartis-Backed Funding
Windward Bio Secures $165 Million to Accelerate Late‑Stage Asthma and COPD Trials
Regional VC Activity Holds Steady Amid Middle‑East Conflict, Highlighting $280M Indian Unicorn Deal
Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs
Recent Deals
Aspen Neuroscience Secures $115M Series C Funding
Venture Catalysts Exits Pee Safe in $32M OrbiMed-Led Minority Recap
BlossomHill Therapeutics Secures $84M Series B Extension Funding
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Mendra Therapeutics Raises $82M Series A to Accelerate Rare Disease Drug Development
AirStrip Secures $50M Growth Credit Commitment From OrbiMed, Plus Additional Preferred Stock Investment
Immunic Raises up to $400M in Oversubscribed Private Placement
Congruence Therapeutics Raises $39.5M in Financing Round Led by Dimension and OrbiMed
Biobeat Raises $50M in Series B Funding
Terremoto Biosciences Raises $108M in Series C Financing Round
SpectronRx Raises $85M From OrbiMed to Expand Isotope Production
BlossomHill Therapeutics Secures $84M Series B Extension